作者
Chang-Qing Bai, Jin-Song Mu, David Kargbo, Ya-Bin Song, Wen-Kai Niu, Wei-Min Nie, Alex Kanu, Wei-Wei Liu, Yao-Ping Wang, Foday Dafae, Tao Yan, Yi Hu, Yong-Qiang Deng, Hui-Jun Lu, Fan Yang, Xiao-Guang Zhang, Yang Sun, Yu-Xi Cao, Hao-Xiang Su, Yu Sun, Wen-Sen Liu, Cheng-Yu Wang, Jun Qian, Liu Liu, Hong Wang, Yi-Gang Tong, Ze-Yuan Liu, Yun-Song Chen, Hong-Quan Wang, Brima Kargbo, George F Gao, Jia-Fu Jiang
发表日期
2016/11/15
期刊
Clinical Infectious Diseases
卷号
63
期号
10
页码范围
1288-1294
出版商
Oxford University Press
简介
Background. During 2014–2015, an outbreak of Ebola virus disease (EVD) swept across parts of West Africa. No approved antiviral drugs are available for Ebola treatment currently.
Methods. A retrospective clinical case series was performed for EVD patients in Sierra Leone–China Friendship Hospital. Patients with confirmed EVD were sequentially enrolled and treated with either World Health Organization (WHO)–recommended supportive therapy (control group) from 10 to 30 October, or treated with WHO-recommended therapy plus favipiravir (T-705) from 1 to 10 November 2014. Survival and virological characteristics were observed for 85 patients in the control group and 39 in the T-705 treatment group.
Results. The overall survival rate in the T-705 treatment group was higher than that of the control group (56.4% [22/39] vs 35.3% [30 …
学术搜索中的文章
CQ Bai, JS Mu, D Kargbo, YB Song, WK Niu, WM Nie… - Clinical Infectious Diseases, 2016